Tel:
Fax:
Email:
Creative Biolabs

Presenilin Antibodies

The pathological features associated with Alzheimer's disease (AD) include the accumulation of extracellular β-amyloid (amyloid β, Aβ) in senile plaques (SP) and neurofibrillary tangles (NFT), which are caused by hyperphosphorylated tau protein. AD has both inherited and acquired causes. Among AD patients, 1-2% have early-onset symptoms, which appear around the age of 40–50 and proceed rapidly. These patients typically have a family history, and their genetic background is widely thought to be the primary cause of the disease. Patients with familial Alzheimer's disease typically have mutant presenilin proteins (PSEN1, PSEN2) or amyloid precursor protein (APP). These mutations cause the accumulation of lengthy chains of amyloid beta.

Presenilin Functions

Researchers have discovered that Psen1 influences the enzyme γ-secretase, which cleaves APP, and regulates how APP is processed. Furthermore, Psen1 can engage in receptor cleavage within the Notch signaling cascade using its enzymatic activity or by directly controlling the activity of γ-secretase. Moreover, it has been demonstrated that PSEN1 might be involved in numerous additional molecular pathways, including:

  • PSEN1 may control the stability of β-catenin, which could be involved in Wnt signaling.
  • PSEN1 regulates the transport and turnover of the epidermal growth factor receptor (EGFR).
  • PSEN1 may have an impact on the activation of PKC and PKC.
  • PSEN1 (and PSEN2) may have an impact on calcium homeostasis, which could be involved in synaptic homeostasis. Several alternatively spliced transcripts of this gene have currently been found by researchers, however, only a small number of the transcripts have clear functions.

Fig 1 Biological function of Presenilin and its role in AD pathogenesis. (Zhang, et al., 2013)Fig.1 Presenilin functions1,2.

PSEN Antibodies Selection Guide

PSEN antibodies from Creative Biolabs are high-quality, trustworthy tools that can help scientists delve more thoroughly into neurodegenerative disorders such as AD. It has been widely employed in a variety of immunoassay procedures and has high specificity and sensitivity. Because of our thorough quality control method, this antibody has good batch-to-batch consistency, making your experimental results more reproducible. Please use the form below to learn more, or contact us directly for further information.

PSEN1 PSEN2
Cat. No Product Name Host Application
NAB2012917LS Mouse Anti-Human Presenilin 1 (CBP3975) Mouse WB
NRZP-0922-ZP3858 Anti-Presenilin 1 Antibody, Clone N35920 (CBP15169) Rabbit WB
NRZP-0822-ZP739 Anti-Presenilin-1 Antibody, Clone N7809P (CBP9180) Mouse WB; ELISA; ICC; IF; IHC; IHC-P; IP
NRZP-0822-ZP3012 Anti-Presenilin-1 Antibody, Clone N8549P (CBP10558) Mouse IHC; IHC-Fr; WB (-)
NRP-0322-P1507 Anti-PSEN1 Monoclonal Antibody (CBP7899) Mouse WB; IHC; ICC; IP
NRZP-1022-ZP3396 Anti-Presenilin 1 BBB Shuttle Antibody Mouse WB; Inhib; In Vitro
NRZP-0922-ZP3859 Anti-Presenilin 1 Antibody, Clone N31222 (CBP15170) Rabbit WB; IP

See all PSEN antibodies

Cat. No Product Name Host Application
NAB-08-PZ1041 Anti-PSEN2 Monoclonal Antibody (CBP1652) Mouse IHC-P
NAB-0720-Z6674 Rabbit Anti-PSEN2 Monoclonal Antibody (CBP3396) Rabbit WB; IHC-P; ICC; IF; IP; FC
NRZP-0822-ZP2101 Anti-Presenilin-2 Antibody, Clone N22711P (CBP10088) Mouse WB
NRZP-0922-ZP3860 Anti-Presenilin 2 Antibody, Clone N26671 (CBP15171) Rabbit WB; IP

See all PSEN antibodies

References

  1. Zhang, Shuting, et al. "Biological function of Presenilin and its role in AD pathogenesis." Translational neurodegeneration 2 (2013): 1-13.
  2. Image retrieved from Figure 4 "Presenilin functions." Zhang et al., 2013, used under [CC BY 2.0] (https://creativecommons.org/licenses/by/2.0).
For Research Use Only. Not For Clinical Use.

Product
Hot Products
Fill out this form for a quote Inquiry Form Send Inquiry
webinar

The Spectrum of Stem Cell-Based Neuronal Models and Their Fit for Purpose

2:00 PM-3:00 PM EDT, December 12, 2024

REGISTER NOW
Inquiry Basket
compare

Send inquiry